XML 130 R14.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Identifiable Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2019
Identifiable Intangible Assets | NOTE 6—Identifiable intangible assets: Identifiable intangible assets consisted of the following:
|  | Gross carrying amount net of impairment |  |  | Accumulated amortization |  |  | Net carrying amount |
|  | December 31, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
|  | (U.S. $ in millions) |
Product rights |  | $ | 19,663 |  |  | $ | 20,361 |  |  | $ | 10,640 |  |  | $ | 9,565 |  |  | $ | 9,023 |  |  | $ | 10,796 |
Trade names |  |  | 600 |  |  |  | 606 |  |  |  | 126 |  |  |  | 91 |  |  |  | 474 |  |  |  | 515 |
In-process research and development (IPR&D) |  |  | 1,735 |  |  |  | 2,694 |  |  |  | — |  |  |  | — |  |  |  | 1,735 |  |  |  | 2,694 |
Total |  | $ | 21,998 |  |  | $ | 23,661 |  |  | $ | 10,766 |  |  | $ | 9,656 |  |  | $ | 11,232 |  |  | $ | 14,005 |
Product rights and trade names Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various categories with a weighted average life of approximately 12 years. Amortization of intangible assets amounted to $1,113 million, $1,166 million and $1,444 million in the years ended December 31, 2019, 2018 and 2017, respectively. As of December 31, 2019, the estimated aggregate amortization of intangible assets for the years 2020 to 2024 is as follows: 2020—$1,019 million; 2021—$856 million; 2022—$794 million; 2023—$790 million and 2024—$773 million. These estimates do not include the impact of IPR&D that is expected to be successfully completed and reclassified to product rights. IPR&D Teva’s IPR&D are assets that have not yet been approved in major markets. Teva’s IPR&D is comprised mainly of the following acquisitions and related assets: various generic products (Actavis Generics)—$1,453 million; various generic products (Rimsa)—$48 million and A USTEDO —$211 million. IPR&D carry intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods. In 2019, Teva reclassified $291 million of products from IPR&D to product rights following regulatory approval, of which $174 million were reclassified in connection with methylphenidate ER. Intangible assets impairment Impairment of identifiable intangible assets amounted to $1,639 million, $1,991 million and $3,238 million in the years ended December 31, 2019, 2018 and 2017, respectively . These amounts are recorded in earnings under intangible assets impairment. Impairments in 2019 mainly consisted of:
| 1. | Identifiable product rights of $ 958 million, mainly related to: (i) $ 647 million due to updated market assumptions regarding price and volume of certain products acquired from Actavis Generics and primarily marketed in the United States , (ii) $ 128 million related to a decrease in future expected sales in Japan as a result of generic competition , and (iii) $123 million related to the discontinuation of certain products from Actavis Generics ’ portfolio in several international markets .
| 2. | IPR&D assets of $681 million, related to: (i) $497 million related to various generic pipeline products acquired from Actavis Generics , due to development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date or discount rate) in the United States , (ii) $125 million related to lenalidomide (generic equivalent of REVLIMID ® ) , due to modified competition assumptions as a result of settlements between the innovator and other generic filers , and (iii) $59 million related to a change in assumptions concerning the future European market share of a number of pipeline products acquired from Actavis Generics.

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration